CD209 and acute myeloid leukemia: Serum levels of soluble DC‐SIGN are reduced in colon cancer patients, and high serum levels of soluble DC‐SIGN correlate with long‐term survival, suggesting that this molecule could serve as a novel prognostic biomarker.110 MICL is detected on acute myeloid leukemia CD34+ stem cells, and mAbs against this molecule cause Ab‐dependent cellular cytotoxicity against both cultured and freshly isolated leukemia cells, suggesting a new therapeutic strategy against acute leukemia.111